Literature DB >> 911605

The influence of age on the response to anticoagulants.

S Husted, F Andreasen.   

Abstract

1 A group of 114 patients on long-term anticoagulant therapy was studied. The daily maintenance dose of both phenprocoumon, bishydroxycoumarin and warfarin was found to be significantly lower in patients aged between 61 and 70 years than in the those between 50 and 60 years of age. The mean daily dose of bishydroxycoumarin, hower, when expressed on a weight basis, was not significantly lower in the elderly. 2 For bishydroxycoumarin but not for phenprocoumon and warfarin there was found a statistically significant correlation between the daily maintenance dose and the weight of the patient. 3 The mean daily dose of both bishydroxycoumarin and warfarin was 30-40% lower than that recommended in the literature. 4 'Correction' was made for potential drug interference by excluding patients in continuous medication with order drugs known to influence the treatment with orally administered anticoagulants. The interindividual variation in dosage requirements of coumarin drug was thereby reduced in the age groups above 60 years. 5 The level of vitamin-k dependent coagulation factors, measured by Owren's 'P and P' method (PP%) was significantly lower (P less than 0.001) in patients of advanced age (between 61 and 70 years) than in younger patients (between 50 and 60 years). 6 The plasma concentration of albumin was significantly lower in patients over 60 years than in those under that age. 7 Correlation (P less than 0.01) was found between the daily maintenance dose of phenprocoumon and the plasma concentraction of albumin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911605      PMCID: PMC1429150          DOI: 10.1111/j.1365-2125.1977.tb00786.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: A COMPARISON OF THE PHARMACODYNAMICS OF DICUMAROL AND WARFARIN IN MAN.

Authors:  R A O'REILLY; P M AGGELER; L S LEONG
Journal:  Thromb Diath Haemorrh       Date:  1964-04-15

2.  The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants.

Authors:  M A PEYMAN
Journal:  Acta Med Scand Suppl       Date:  1958

3.  Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

4.  Problems associated with long-term anticoagulant therapy. Observations in 139 cases.

Authors:  J W POLLARD; M J HAMILTON; N A CHRISTENSEN; R W ACHOR
Journal:  Circulation       Date:  1962-02       Impact factor: 29.690

5.  The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin.

Authors:  P A OWREN; K AAS
Journal:  Scand J Clin Lab Invest       Date:  1951       Impact factor: 1.713

6.  Individual variation in the response to phenprocoumon.

Authors:  S Husted; F Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

7.  Hemorrhagic complications of anticoagulant therapy.

Authors:  W W Coon; P W Willis
Journal:  Arch Intern Med       Date:  1974-03

Review 8.  Drug interactions with coumarin anticoagulants. 2.

Authors:  J K Weser; E Sellers
Journal:  N Engl J Med       Date:  1971-09-02       Impact factor: 91.245

9.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

10.  Problems encountered in long-term treatment with anticoagulants.

Authors:  S Husted; F Andreasen
Journal:  Acta Med Scand       Date:  1976
View more
  13 in total

1.  Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.

Authors:  D Holmes; E Nuesch; J M Houle; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications.

Authors:  A Hämmerlein; H Derendorf; D T Lowenthal
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

3.  The potentiation of acenocoumarol anticoagulant effect by amiodarone.

Authors:  M Arboix; M E Frati; J R Laporte
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

4.  A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment.

Authors:  J C Forfar
Journal:  Br Heart J       Date:  1979-08

5.  Comparison of a new microcrystalline dicoumarol preparation with warfarin under routine treatment conditions.

Authors:  D Lockner; C Paul
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

6.  Factors affecting warfarin requirements. A prospective population study.

Authors:  P A Routledge; P H Chapman; D M Davies; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1979-06-12       Impact factor: 2.953

7.  An acenocoumarol dose algorithm based on a South-Eastern European population.

Authors:  Tudor Radu Pop; Ştefan Cristian Vesa; Adrian Pavel Trifa; Sorin Crişan; Anca Dana Buzoianu
Journal:  Eur J Clin Pharmacol       Date:  2013-06-18       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Effect of age and sex on acenocoumarol requirements.

Authors:  M Arboix; J R Laporte; M E Frati; M Rutllan
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

10.  Population pharmacokinetics of racemic warfarin in adult patients.

Authors:  D R Mungall; T M Ludden; J Marshall; D W Hawkins; R L Talbert; M H Crawford
Journal:  J Pharmacokinet Biopharm       Date:  1985-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.